JUN. 1.2005 11:51AM AVENTIS US PAT DEPT

RECEIVED CENTRAL FAX CENTER NO. 5738

4 0005

Р.

JUN 0 1 2005

PTO/SB/21 (09-04)
Approved for use through 07/31/2005. OMB 0861-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/644,150 TRANSMITTAL Filing Date August 20, 2003 FORM First Named Inventor Jean-Marie STUTZMANN et al. Art Unit 1623 Examiner Name G. Krishnan (to be used for all correspondence after inhial filing) Attorney Docket Number ST98048 US DIV Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmillal Form Drawing(s) Appeal Communication to Board Fee Altached Licensing-related Papers of Appeals and interferences ~ Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Altomey, Revocation Affidavits/declaration(s) Change of Correspondence Address Status Letter Other Enclosure(s) (please Identify Terminal Disclatmen Extension of Time Request below): Express Abandonment Request Request for Refund 1. Exhibit A - 10 pgs 2. Exhibit B - 22 pgs 9. Exhibit C - 4 pgs CD, Number of CD(s) Information Disclosure Statement 4. Exhibit D - 9 pgs Landscape Table on CD **Certified Copy of Priority** Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name AYENTIS PHARMACEUTICALS INC. Signature Printed name oseph D. Rossi Date Reg. No. Jugle 1, 2005 47,038 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 703-872-9306 Total No. of Pages Transmitted: 47 Signature Date Typed or printed name Paul Irvine June 1, 2005

This collection of information is required by 37 CPR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CPR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for roducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

NO. 5738 P. 2

JUN 0 1 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of STUTZMANN, et al.

Examiner: Ganapathy, KRISHNAN

ANN, et al.

Art Unit:

1623

Application No.: 10/644,150

Filed:

August 20, 2003

TELEFAX CERTIFICATE

Title:

NOVEL THERAPEUTIC USE OF LOW MOLECULAR WEIGHT HEPARINS

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

June 1, 2005

Date of

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Office Communication dated May 5, 2005 and the Office Action dated August 11, 2004 ("the Action"), reconsideration is respectfully requested in view of the amendments and/or remarks as indicated below:

- Amendments to the Claims are reflected in the listing of the claims that begins on page 2 of this paper.
- Remarks/Arguments begin on page 4 of this paper.